



CogniBen™

PATENTED COMPOSITION

Comprehensive Cognitive Support*

Serving unmet needs with formulations possessing immediate action and efficacy.

CogniBen™ supports:

- ⚙️ Optimal Cognitive Function*
- ⚙️ Increased Concentration, Focus, and Energy*
- ⚙️ Restoration of Mental Alertness*



SYNERGISTIC BLEND | SAFE | HIGHLY EFFICACIOUS

Key Ingredients of Patented Synergistic CogniBen™ Formulation

- Ginkgo biloba**
 a botanical with proven cognitive benefits; supports improved blood flow to the brain and contributes to optimal cognitive function and concentration*^{1,2}
- Phenylethylamine (PEA)**
 known to modulate dopaminergic, serotonergic, and adrenergic activities, optimizing psychological energy/focus and enhanced concentration*³
- Caffeine**
 in an amount equal to approximately one-half cup of coffee, caffeine modulates the adenosine family of receptors in the brain. Caffeine's actions may enhance brain activity and mental alertness*⁴

Supplement Facts

Serving Size 1 tablet	
Servings Per Container 30	
Amount Per Serving	
TRN 101 Blend *	500 mg [†]
<i>Ginkgo biloba</i> leaf extract, Phenylethylamine hydrochloride (PEA HCl), and Caffeine	
*Daily Values not established.	

Other Ingredients: Microcrystalline cellulose, starch, silicon dioxide, magnesium stearate, cellulose-based coating

Suggested Use: Take 1 tablet on an empty stomach before breakfast. Tablet should not be taken within 5-6 hours before bedtime. Use under the supervision of, or as directed by, a health care practitioner.

Gluten Free | non-GMO | Soy Free | Vegetarian


*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

CogniBen™ is the first multi-target modulator for cognitive support.*

Figure 1: Effect of 1 week treatment with PEA, *Ginkgo biloba*, and Caffeine on PEA urine levels in adult subjects with attention and focus issues. Administration of the ingredient combination found in Cogniben™ and its effect on urine PEA levels.

The synergistic blend and ratio of ingredients in CogniBen™ are key to its demonstrated efficacy.* When combined with PEA, *Ginkgo biloba* may markedly improve PEA bioavailability (figure 1) and efficacy (figure 2).^{5*} The combined cognitive support properties, neuronal network modulation activity, and stimulating effects of CogniBen's™ ingredients induce a broad spectrum of benefits in a relatively short period of time.*


The importance of the dopaminergic, serotonergic, cholinergic, and adrenergic neuronal networks in supporting those with cognitive issues is supported by significant clinical research.^{6,7*}



Safety and Efficacy of CogniBen on Adults with Symptoms of Cognitive Impairment.

Figure 2. Safety and Efficacy of CogniBen on Adults with Symptoms of Cognitive Impairment.

Effect of CogniBen Dose Titration on Total Average Symptom Score



Dosing was titrated from half tablet CogniBen™ daily on Day 0 to two tablets daily by Day 14 and maintained for an additional 5 weeks. A 42-percent reduction in the Average Symptom Score was observed over the course of the seven-week study.

A recent single-blind, dose titration, outpatient study evaluated the efficacy of CogniBen™ in 10 adults (18 to 55 years) with symptoms of cognitive impairment. Subjects were titrated from half tablet of CogniBen™ daily, up to the maximal allowed dose of two tablets per day by the end of the 2nd week. This dose was maintained for an additional 5 weeks. Subjects' symptoms, well-being, and improvements were assessed via questionnaires at baseline and subsequent visits.

The primary efficacy endpoint was the average change from baseline to endpoint in total average symptom score.⁸

As a follow-up to this initial study, a 60 person study is in process.

1. Mashayekh A, Pham DL, Yousem DM, et al. *Neuroradiology* 2011;53:185-191.
2. Yang G, Wang Y, Sun J, et al. *Curr Top Med Chem* 2016;16:520-528.
3. Knoll J, Miklya I, Knoll B, et al. *Life Sci* 1996;58:2101-2114.
4. Glade MJ. *Nutrition* 2010;26:932-938.
5. White HL, Scates PW, Cooper BR. *Life Sci* 1996;58:1315-1321.
6. Takahashi RN, Pamplona FA, Prediger RD. *Front Biosci* 2008;13:2614-32.
7. Celada P Puig M, Artigas F. *Front Integr Neurosci* 2013; 7:25
8. Unpublished Research. Assessment of a Novel Nutraceutical Blend (TRN 101™) on Adults. June 2017.



For orders and product information visit us at www.trinutra.com

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.